Quote this publication Share Print

DACARBAZINE LIPOMED, (dacarbazine), alkylating agent

Opinions on drugs - Posted on Jul 19 2017

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

No clinical benefit demonstrated in the next-line treatment of advanced melanoma after failure of immunotherapies and/or therapies targeted at B-RAF mutations.

Insufficient actual benefit in other situations, especially in first–line treatment, due to the role of immunotherapy and therapies targeting B-RAF mutations.


  • Before the availability of immunotherapy and so-called targeted therapies in 2012, dacarbazine was commonly used as a first-line treatment for advanced melanoma, despite the absence of any demonstrated effect on survival.
  • Immunotherapy and anti-BRAF therapies alone or in combination with anti-MEK agents have supplanted dacarbazine due to the demonstration of a superior efficacy in terms of disease-free survival and/or overall survival.

  • Cytotoxic agents, including dacarbazine, are now a last-line treatment.




Actual benefit




Improvement in actual benefit

V (absence)


Contact Us

Évaluation des médicaments